Skip to content

Study · Not a test of the peptide alone · 2013

4 results

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.

Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M

Journal of medical economics31 May 2013Cited by 21 (Europe PMC)

PMID23659201 (opens in a new tab)DOI10.3111/13696998.2013.803110 (opens in a new tab)PepBankPUB-23659201
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a Spanish diabetes model, once-weekly exenatide had lower projected costs than twice-daily exenatide.

    In plain wordsComputer projections showed lower costs with weekly exenatide than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProjected cost
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Exenatide twice daily
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    When compared with EBID, EQW was the dominant strategy, i.e., less costly and more effective.
    2 context sentences
    Summary · context
    The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with T2DM treated with EQW, EBID, and IG.
    Summary · context
    The base case included patients with a BMI > 30 kg/m(2), which is in line with current prescription restrictions in Spain.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a Spanish diabetes model, once-weekly exenatide had greater projected effectiveness than twice-daily exenatide.

    In plain wordsComputer projections showed greater effectiveness with weekly exenatide than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProjected effectiveness
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Exenatide twice daily
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    When compared with EBID, EQW was the dominant strategy, i.e., less costly and more effective.
    2 context sentences
    Summary · context
    The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with T2DM treated with EQW, EBID, and IG.
    Summary · context
    The base case included patients with a BMI > 30 kg/m(2), which is in line with current prescription restrictions in Spain.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a Spanish diabetes model, weekly exenatide had an incremental cost-effectiveness ratio of €12,084 per QALY versus insulin glargine.

    In plain wordsComputer projections estimated €12,084 per QALY gained with weekly exenatide versus insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Measurements

    Incremental cost-effectiveness ratio
    12,084 EUR/QALY
    versus insulin glargine

    Source sentences

    Summary
    When compared to IG, the incremental cost-effectiveness ratio was estimated at €12,084 per QALY gained.
    2 context sentences
    Summary · context
    The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with T2DM treated with EQW, EBID, and IG.
    Summary · context
    The base case included patients with a BMI > 30 kg/m(2), which is in line with current prescription restrictions in Spain.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the diabetes model, exenatide projections remained robust across the tested sensitivity scenarios.

    In plain wordsComputer projections remained robust across the tested scenarios.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSensitivity analysis robustness
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Sensitivity analysis indicated that the model projections were robust to the various scenarios tested.
    2 context sentences
    Summary · context
    The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with T2DM treated with EQW, EBID, and IG.
    Summary · context
    The base case included patients with a BMI > 30 kg/m(2), which is in line with current prescription restrictions in Spain.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.